HRT Financial’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

HRT Financial’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-174,189	Closed	-$6.69M	–	3400
2023 Q2	$6.69M	Buy	+174,189	New	+$4.47M	0.06%	215
2023 Q1	–	Sell	-13,134	Closed	-$344K	–	3455
2022 Q4	$344K	Buy	+13,134	New	+$291K	﹤0.01%	1648
2020 Q1	–	Sell	-24,364	Closed	-$143K	–	1482
2019 Q4	$143K	Buy	24,364 +19,708	+423%	+$107K	0.01%	989
2019 Q3	$24K	Buy	4,656 +2,439	+110%	+$16.2K	﹤0.01%	1331
2019 Q2	$17K	Buy	+2,217	New	+$33.8K	﹤0.01%	714

HRT Financial's KDNY Position: Q3 2023 in Review

HRT Financial sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 174,189 shares — an estimated $6.69M sold.

HRT Financial first reported a position in KDNY in Q2 2019 and held it in 5 quarters. The position peaked at $6.69M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

HRT Financial reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
HRT Financial sold 174,189 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $6.69M.
HRT Financial first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
HRT Financial's Chinook Therapeutics, Inc. Common Stock position peaked at $6.69M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on HRT Financial's 13F filing for Q3 2023, filed 13 Nov 2023.